Archive | January, 2021

Hot Mandate: US-Based VC Focuses on Deep Technologies in Healthcare, Including Computational Drug Discover & AI-Driven Diagnostics

29 Jan

A venture capital firm with offices in California backs entrepreneurs applying deep and differentiated technology to transform giant industries. The firm focuses on seed and series A investments and has over $2B AUM. The firm usually makes seed investments in the range of $250K – $1M and venture-stage investments from $1M-$4M and may use both convertible notes or straight equity. The firm may lead or co-invest in a syndicate and looks to add unique value to entrepreneurs with a strong Equity Partner network, operational experience and technical background.

The firm invests in several verticals and is focused on deep technologies such as AI, advanced materials, quantum computing, etc. In the healthcare space, the firm is focused on the entire continuum including computational drug discovery, AI-driven diagnostics, better/faster clinical trials and technologies used by payers and providers to better understand and manage risk and drive better outcomes. The common theme is that the startup’s underlying technology be novel and data-driven. The firm does not invest in biopharma or traditional medical devices/diagnostics with a standard regulatory pathway.

The firm requires that startups have some type of proof-of-concept and traction, and prefers experienced/proven management teams and entrepreneurs that are introduced through the firm’s network. The firm typically seeks a board seat when leading an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot Mandate: UK-Based Corporate VC Invests in Digital Health, Digital Medical Devices and Big Data Analytics Platforms

29 Jan

Established 2015 and headquartered in the UK, the firm is the corporate venture capital arm of a global generic manufacturer that is listed on the London Stock Exchange. The firm can invest up to $5M to a round and will participate in rounds for digital health companies at all stages, as early as seed and through later venture rounds. The firm is open to working with companies globally.

Within digital health, the firm is seeking companies that are in the prevention and adherence space as well as digital medical devices and big data analytics platforms that address chronic diseases (Diabetes, Obesity and Cardiovascular), respiratory diseases, oncology, consumer and mental health. Past investments in the space include a wearable nicotine delivery device with integrated software and data analytics component to aid in smoking cessation.

The firm prefers to work with management teams with a track record in the space and a strong business plan.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Hot Mandate: Private Equity Subsidiary of European Banking Group Interested In Novel Digital Health, Including AI & Machine Learning Opportunities in Healthcare

29 Jan

The private equity subsidiary of a European banking group carries out venture capital, growth capital and buyout activities. The firm supports business leaders at all stages of their companies’ development, from seed phase to buyout, by providing them with the means and the time required to implement their transformational projects. Using its own funds (€3.0 billion), the firm makes investments tailored to the time horizons and growth strategies of the companies in which it invests, whether in France, Canada, the United States, Germany or Switzerland. The firm makes equity investments in progressive stages, ranging up to $10m and typically leads the round – although the firm is open to co-investing.

The firm is interested in all areas of technology, and devotes about half of its Fund to healthcare and the other half to the Digital sector covering IT, Telecom, etc. The firm is also interested in novel healthcare IT opportunities such as applications of AI and machine learning in healthcare. The firm seeks highly differentiated, disruptive technology; and does not invest in “me-too” products. 20% of the fund’s investments are in pre-revenue companies; 40% are in companies that are revenue-generating but not yet at break-even, and 40% are in profitable companies.

The firm seeks disruptive technology companies led by high-quality management teams, and prefers to work with managers who have had previous successes in technology start-ups. Additionally, the firm welcome the opportunity to co-invest with top tier investors. The firm will want to have a representation on the Board of Directors.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

Life Science Nation’s 2021 Partnering Theme: Bigger and Better

28 Jan

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

Life Science Nation (LSN) is ramping up its partnering theme for 2021 by emphasizing global roadshow preparation for the 4,500 fundraising CEOs and scientist-entrepreneurs at our cross-border, cross-domain, digital partnering events. LSN’s infrastructure is designed to help early-stage companies prepare for the capital and partnering journey with products and services including, but not limited to:

  • Two databases: Investor Platform with 10,000 global investors and strategic partners, and Company Platform with 60,000 life science companies.
  • 300+ university, regional, and governmental tech hubs that use LSN partnering events to help their local technology companies get global exposure.
  • Growing global super-structure consisting of a cross-border, cross-domain, two-way bridge for licensing and funding life science technology assets.
  • Quarterly Healthtech Partnering Week (HPW), consisting of three partnering conferences: RESI, 4D Meets AI, and Longevity, Health & Innovation (co-organized with Mary Furlong & Associates), that further develops our global footprint as a major force in connecting buyers and sellers in the international arena.
  • Focus on Cures Accelerator for sourcing, vetting, developing and preparing key companies for global licensing and fundraising campaigns.
  • I-Bank, Boston Innovation Capital, for licensing and funding campaigns for elite healthcare technology companies internationally.

LSN has invested 8 years in building out this global network, and our 2021 growth will serve as a compass toward the future. We look forward to developing our products, services, as well as deep alliances with the global players leveraging this unique golden age of life science, where breakthrough and game-changing technology is in no short supply.

 

Join the Healthtech Partnering Week Agenda

28 Jan

By Rory McCann, Marketing Manager & Conference Producer, LSN

Life Science Nation (LSN)’s Healthtech Partnering Week, March 15-19, 2021, has announced its agenda, and we hope you’ll consider taking part! Whether you are a fundraising CEO, scientist-entrepreneur, service provider, regional tech hub, or investor, there are ways to get involved and take advantage of the weeklong partnering event by attending, speaking, pitching, sponsoring, or exhibiting.

Investors

Digital Redefining Early Stage Investments (RESI) is a powerful gathering focused on early-stage funding across all verticals of life science. One of its strongest connection tools is its live investor panels offering insights into the early-stage fundraising process. If you’re an investor working with companies developing cutting edge biotech, medtech, and healthtech advancing the power and potential of healthcare and medicine, apply to join a panel at RESI.

4D Meets AI is hosting panels where active investors are joined by their portfolio companies to discuss funding, partnerships, and the future of AI in life science and healthcare. Join us for four live panels, each delving into one of the 4Ds: drugs, devices, diagnostics, and digital health. If you’re an investor in AI in healthcare and have a portfolio company to highlight, apply to participate on a 4D Meets AI panel.

Investors seeking opportunities in age-tech and longevity is a powerful and growing community. If you work with companies developing technology to advance Senior Care, Cardiovascular Disease, Oncology, Central Nervous System (CNS) Disease, Diabetes, Chronic Respiratory Disease (CRD), Hearing Loss & Sight Deterioration, Arthritis, or Mental Health Conditions, apply to join the conversation at Longevity, Health & Innovation.

Early-Stage Companies

The Innovator’s Pitch Challenge (IPC) is an opportunity for early-stage companies actively raising seed capital (25K-2MM), Series A (2MM-10MM), or Series B (10MM-50MM) to gain additional exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. Participating companies pay registration and a pitching fee to host their company materials on the Live Agenda and participate in the live pitch session.

Companies can learn more and apply for each Healthtech Partnering Week conference:

Tech Hubs

Tech hubs are invited to offer constituents to participate in Healthtech Partnering Week with special offers specifically for them. Constituents can save 50% on registration and receive a free dedicated landing page for optimal exposure on the conference Live Agenda. Additionally, LSN hosts partnering webinars to help CEOs make strong connections with 350+ healthcare investors, including a training workshop to help CEOs seeking financing to move their technologies forward in the development process.

Service Providers & Strategic Partners

Sponsorship helps companies gain visibility in the early-stage life science community by leveraging our close-knit network of key decision-makers to make promising connections. If you fall into any of these categories, LSN’s Business Development team would like to connect to share how Healthtech Partnering Week can help you meet your goals:

  • Global investors, channel partners, strategic partners and big pharma sourcing technology assets for their pipeline, channels and new silos
  • Service providers selling their services to funded CEOs, establishing relationships with global strategic partners and expanding market presence.
  • Investors expanding their portfolio through technology assets, finding investment partners for joint deal syndication, and finding service providers to help develop their portfolio.

View our complete offerings in the Sponsorship Brochure and let us know how our dedicated team can add value to your sponsorship experience.

Introducing The Mandate Newsletter

28 Jan

By Elizabeth Murphy, Manager of Business Development, LSN

Life Science Nation (LSN) is happy to announce The Mandate Newsletter, a weekly newsletter featuring investors and strategic partners seeking AI technology assets within drugs, devices, diagnostics, and digital health and early-stage firms for investment, pipeline, and channel development.

The Mandate Newsletter is a part of LSN’s growing community of leaders in early-stage AI advancing healthcare and life science through innovative smart technology. In addition to sharing investor mandates and industry insights, The Mandate Newsletter will provide opportunities for investors, fundraising CEOs, and strategic partners to get involved with the 4D Meets AI digital partnering conference series, a conference designed to connect buyers and sellers based on product fit and stage of development, specifically for those innovating AI tech within drugs, devices, diagnostics, and digital health (4Ds).

Sign up to receive the weekly Mandate Newsletter, and find out how to get involved with 4D Meets AI, March 18-19, 2021.

Hot Investor Mandate: Corporate Venture Arm of Large Asia Company Seeks Therapeutics, Devices, and Digital Health Products in Pain Management, Critical Care, and More

28 Jan

A corporate venture arm of a diversified business based in Asia is focused on three primary sectors, and one of them includes healthcare. The team has offices in key hub cities in USA, and the fund has an evergreen structure looking to allocate between $1-3 million per deal initially and up to $5 million over the life of the investment. The firm is seeking to invest in approximately 2-4 companies over the next 12 months and are open to investing in companies across the globe.

Sectors of interest include: pharmaceuticals, medical device and digital health. Therapeutic and product areas of interest include: Pain, critical care, musculoskeletal disease, kidney disease, patient monitoring technologies, bioprocessing technologies, digital therapeutics. The firm is open to all stages of investment, with a general preference toward companies with at least some early clinical data.

The firm invests in private companies and is willing to work with all types of management teams including incomplete teams. The firm generally requests at least an observer seat following investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries